|Bid||0.3700 x 800|
|Ask||0.3800 x 1800|
|Day's Range||0.3633 - 0.4200|
|52 Week Range||0.3000 - 1.3200|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 20, 2019 - Mar 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.85|
NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled "Systems and Methods for Enabling Optical Transmission of Data Between a Sensor and a Smart Device." The patent will allow Dario to develop paired smartphone devices that can collect and analyze real-time medical data and provide immediate and highly detailed, personalized data reports to the user. Once collected, this data can be shared with healthcare providers through the DarioEngage™ platform to facilitate digital health interventions based on the data analysis. "Dario's business and product strategy is guided by evidence that shows that increased user engagement and direct empowerment of individuals to manage their personal health leads to better medical outcomes," said Erez Raphael, DarioHealth's chief executive officer.
DURHAM, North Carolina and NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario" (DRIO), a leading, global digital therapeutics company, to expand access to a personalized digital health management platform for patients with chronic diseases. Under the terms of the agreement, Dance Biopharm will integrate its gentle mist smart inhaler into DarioHealth's digital therapeutics platform to provide patients automated, real-time treatment data through an advanced mobile application.
NEW YORK and CAESAREA, Israel , Aug. 28, 2019 /PRNewswire/ -- Leading global digital therapeutics company DarioHealth Corp. (Nasdaq: DRIO) today announced that DarioHealth's Chief Executive Officer, Erez ...
NEW YORK and CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L") as part of its UK Israel Dangoor Health Initiative (the "Initiative"), which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients.
NEW YORK and CAESAREA, Israel , Aug. 13, 2019 /PRNewswire/ -- Q2 2019 Revenue of $1.65 million , a 20% decline from Q2 2018 Record 1H 2019 Revenue of $3.89 million , a 2% increase over 1H 2018 Expense ...
NEW YORK and CAESAREA, Israel, Aug. 12, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, presented new clinical data yesterday at the American Association of Diabetes Educators ("AADE") conference in Houston, Texas, which showed remarkable improvements in average blood-glucose levels and in-range measurements in patients with diabetes using Dario's digital therapeutics platform and dedicated one-on-one personal health coaching.
Earnings Discussion and Business Update Scheduled for 9:00 am EDT NEW YORK and CAESAREA, Israel , Aug. 7, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: ...
New offering enables users to integrate blood pressure readings into the Dario mobile app to gain better understanding and control of overall health. NEW YORK and CAESAREA, Israel, July 30, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO), ("DarioHealth" or "Dario"), a leading global, digital therapeutics company, announced today the addition of a new digital monitoring solution on its Dario app platform that will allow patients to monitor their blood pressure throughout the day, in addition to their blood glucose levels. The Dario Blood Pressure Monitoring System assists patients with hypertension and is a critical part of DarioHealth's strategy to go beyond diabetes to reach patients with a variety of chronic conditions.
DarioHealth Corp. (NASDAQ:DRIO) shareholders should be happy to see the share price up 24% in the last week. But will...
NEW YORK and CAESAREA, Israel, July 25, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (DRIO), today announced that its CE certificate covers a USB-C connector enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The USB-C connector is used to transfer power and communication signals between Android smart mobile devices and the Dario meter, and ensures that consumers, beginning with the Europe market region, will receive the same quality user experience with DarioHealth on the latest Android smart phone devices.
NEW YORK and CAESAREA, Israel, July 8, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO) today announced that on July 5, 2019, it received notification from Nasdaq that the Company has been granted an additional 180-day compliance period, or until December 23, 2019, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the "Rule"). Nasdaq's determination to grant the additional 180-day compliance period was based on the Company meeting the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company having provided written notice of its intention to cure the deficiency during the second compliance period, including effecting a reverse stock split if necessary.
SAN FRANCISCO, June 11, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global Digital Therapeutics (DTx) company with connected devices, mobile software and large data solutions presented two studies reporting new real-world results at the American Diabetes Association's (ADA) 79th Scientific Sessions in San Francisco, California. The studies provide additional insights on how the use of Dario's mobile applications, within a complete digital therapeutics solution, may promote behavioral modifications and enhanced individual engagement with diabetes management.
NEW YORK, CAESAREA, Israel and FORT COLLINS, Colorado, June 4, 2019 /PRNewswire/ -- Global #digitaltherapeutics innovator DarioHealth Corp. (DRIO) today announced an agreement with Functional Medicine Center of Fort Collins, based in Fort Collins, CO (https://functionalmedicinefortcollins.com/).
NEW YORK and CAESAREA, Israel, May 29, 2019 /PRNewswire/ -- Global digital therapeutics (DTx) innovator, DarioHealth Corp. (DRIO), today announced its participation at the annual conference of the American Diabetes Association (ADA) in San Francisco on June 7th-10th. At the ADA conference, Dario will publish several studies performed using de-identified data from thousands of users accumulated in its data base. The studies demonstrate the benefits of Dario's DTx solution to help improve life with diabetes and achieve clinically proven results.
CAESAREA, Israel, May 22, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or the "Company"), a global digital therapeutics innovator, today announced the pricing of an underwritten public offering of 4,855,341 shares of common stock at a price to the public of $0.60 per share and pre-funded warrants to purchase 7,175,525 shares of common stock at a price to the public of $0.5999 per pre-funded warrant for aggregate gross proceeds of approximately $7,200,000, before underwriting discounts and offering expenses. The pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable until exercised in full and include a beneficial ownership blocker of 9.99%. The offering is expected to close on or about May 24, 2019, subject to the satisfaction of customary closing conditions.
CAESAREA, Israel, May 21, 2019 /PRNewswire/ -- DarioHealth Corp. (DRIO) ("DarioHealth" or the "Company"), a global digital therapeutics innovator, today announced that it intends to offer and sell shares of common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Craig-Hallum Capital Group is acting as sole managing underwriter for the offering.
- Earnings and business update call scheduled for 9:00 am ET today - Record Q1 revenues of $2.2 million , representing 32% sequential revenue growth over 4Q 2018 - Record Q1 billings of $2.8 million (non-GAAP), ...
Earnings Discussion and Business Update Scheduled for 9:00 am EDT NEW YORK and CAESAREA, Israel , May 7, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) ...
DarioHealth's mission is to support people with diabetes and other chronic conditions in the U.S. and around the world. ARLINGTON, Virginia, NEW YORK and CAESAREA, Israel, May 3, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (DRIO), today announced that it is partnering with the American Diabetes Association as a Living Red Sponsor of NYC - Step Out®: Walk to Stop Diabetes®.
WASHINGTON and CAESAREA, Israel, April 30, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ: DRIO), today announced that it is now a member of the Digital Therapeutics Alliance (DTA) (www.DTxAlliance.org). Dario's acceptance to the DTA as a new member demonstrates its commitment to the core principles of the DTA - encouraging data-driven integration and utilization of digital therapeutics across the healthcare industry, engaging patients and enabling healthcare providers to intelligently manage and expand the delivery and quality of patient care, optimizing clinical treatment pathways, enhancing patient outcomes, increasing overall healthcare value and educating patients, providers, payers, and other healthcare industry stakeholders, on the value and improved health outcomes delivered through digital therapeutics.
New version V4.2.0 is a testament to Dario's relentless commitment to patients with chronic conditions. CAESAREA, Israel, April 10, 2019 /PRNewswire/ -- Global digital therapeutics innovator, DarioHealth Corp. (DRIO), today announced the launch of a new version of its acclaimed Dario® system and DarioEngage™ platform. The Company's first goal is driving ever stronger user engagement by implementing a more intuitive and personalized experience in the individual user application as well as in the coaching platform.